Evotec Extends and Broadens Research Agreement with Cubist Pharmaceuticals
(Thomson Reuters ONE) -
Evotec AG / Evotec Extends and Broadens Research Agreement with Cubist Pharmaceuticals processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
- Collaboration expanded to include integrated fragment-based drug discovery
activities on additional antibacterial targets -
Hamburg, Germany - 25 February 2010: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX) today announced that it has extended its research agreement with Cubist
Pharmaceuticals, Inc. (NASDAQ: CBST) to the end of 2010. Under the contract
extension, Evotec will provide additional fragment-based drug discovery
expertise using its proprietary platform, EVOlution(TM), which includes fragment
screening, structural biology and protein crystallography, to discover and
profile novel compounds against additional antibacterial targets selected by
Cubist.
Evotec and Cubist have collaborated since July 2009, successfully progressing
drug discovery programmes. Over the course of 2010, Evotec will continue and
expand its support of Cubist's discovery activities. A key benefit of Evotec's
fragment-based drug discovery platform is its versatility, combining biochemical
and biophysical techniques including nuclear magnetic resonance (NMR), surface
plasmon resonance (SPR) and x-ray crystallography, thus allowing the design of
target-specific strategies.
Dr Mark Ashton, Executive Vice President, Business Development of Evotec
commented: "This is further validation of our expertise and capabilities in
fragment-based drug discovery. We enjoy the close and productive relationship we
have with Cubist's scientists and look forward to carry on adding significant
value to their portfolio of antibacterial programmes."
No financial details are disclosed.
About EVOlutionTM
EVOlutionTM is Evotec's fragment-based drug discovery platform which combines
biochemical and biophysical techniques including nuclear magnetic resonance
(NMR), surface plasmon resonance (SPR) and x-ray crystallography for the
screening of low molecular weight compounds and fragments. By the combination of
the orthogonal screening technologies, Evotec's fragment screening platform is
capable of screening a more diverse set of biological targets than other
fragment screening approaches, as well as being able to screen the fragments in
a high-throughput mode. The benefit of this is the ability to identify active
fragments for numerous classes of biological targets in a short space of time.
For further information, please see: www.evotec.com/fragment-based drug
discovery
About Fragment-based Drug Discovery
Fragment-based drug discovery (FBDD) is a new paradigm in drug discovery that
utilises very small molecules - fragments of more complex molecules - to
generate efficient starting points for drug discovery. This approach thus
provides the opportunity to effectively manage the molecular weight and overall
complexity of drug candidates, a recognised success factor in drug development.
Contact Evotec AG:
Dr Werner Lanthaler, Chief Executive Officer, Phone: +49.(0)40.56081-242,
werner.lanthaler(at)evotec.com
Forward-looking statements
Information set forth in this press release contains forward-looking statements,
which involve a number of risks and uncertainties. Such forward-looking
statements include, but are not limited to, statements about our expectations
and assumptions concerning our strategic collaborations, our regulatory,
clinical and business strategies, the progress of our clinical development
programmes and management's plans, objectives and strategies. These statements
are neither promises nor guarantees, but are subject to a variety of risks and
uncertainties, many of which are beyond our control, and which could cause
actual results to differ materially from those contemplated in these
forward-looking statements. In particular, the risks and uncertainties include,
among other things: risks that product candidates may fail in the clinic or may
not be successfully marketed or manufactured; the risk that we will not achieve
the anticipated benefits of our collaborations, partnerships and acquisitions in
the timeframes expected, or at all; risks relating to our ability to advance the
development of product candidates currently in the pipeline or in clinical
trials; our inability to further identify, develop and achieve commercial
success for new products and technologies; the risk that competing products may
be more successful; our inability to interest potential partners in our
technologies and products; our inability to achieve commercial success for our
products and technologies; our inability to protect our intellectual property
and the cost of enforcing or defending our intellectual property rights; our
failure to comply with regulations relating to our products and product
candidates, including FDA requirements; the risk that the FDA may interpret the
results of our studies differently than we have; the risk that clinical trials
may not result in marketable products; the risk that we may be unable to
successfully secure regulatory approval of and market our drug candidates; and
risks of new, changing and competitive technologies and regulations in the U.S.
and internationally.
The list of risks above is not exhaustive. Our most recent Annual Report on Form
20-F, filed with the Securities and Exchange Commission, and other documents
filed with, or furnished to the Securities and Exchange Commission, contain
additional factors that could impact our businesses and financial performance.
We expressly disclaim any obligation or undertaking to release publicly any
updates or revisions to any such statements to reflect any change in our
expectations or any change in events, conditions or circumstances on which any
such statement is based.
[HUG#1388386]
--- End of Message ---
Evotec AG
Schnackenburgallee 114 Hamburg Germany
WKN: 566480;ISIN: DE0005664809 ;Index:Prime All Share,TECH All Share,CDAX,MIDCAP,HDAX;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Unternehmensinformation / Kurzprofil:
Datum: 25.02.2010 - 07:29 Uhr
Sprache: Deutsch
News-ID 12897
Anzahl Zeichen: 0
contact information:
Town:
Hamburg
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 195 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Evotec Extends and Broadens Research Agreement with Cubist Pharmaceuticals"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
